MXPA04012970A - Preparacion farmaceutica y metodo de tratamiento de malignidad humana con carencia de arginina. - Google Patents

Preparacion farmaceutica y metodo de tratamiento de malignidad humana con carencia de arginina.

Info

Publication number
MXPA04012970A
MXPA04012970A MXPA04012970A MXPA04012970A MXPA04012970A MX PA04012970 A MXPA04012970 A MX PA04012970A MX PA04012970 A MXPA04012970 A MX PA04012970A MX PA04012970 A MXPA04012970 A MX PA04012970A MX PA04012970 A MXPA04012970 A MX PA04012970A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical preparation
human malignancies
arginine deprivation
pharmaceutical composition
Prior art date
Application number
MXPA04012970A
Other languages
English (en)
Spanish (es)
Inventor
Hung Lo Wai
Original Assignee
Bio Cancer Treatment Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04012970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Cancer Treatment Int Ltd filed Critical Bio Cancer Treatment Int Ltd
Priority claimed from PCT/GB2003/002665 external-priority patent/WO2004000349A1/en
Publication of MXPA04012970A publication Critical patent/MXPA04012970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA04012970A 2002-06-20 2003-06-20 Preparacion farmaceutica y metodo de tratamiento de malignidad humana con carencia de arginina. MXPA04012970A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39075702P 2002-06-20 2002-06-20
PCT/CN2002/000635 WO2004001048A1 (en) 2002-06-20 2002-09-09 Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
PCT/GB2003/002665 WO2004000349A1 (en) 2002-06-20 2003-06-20 Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation

Publications (1)

Publication Number Publication Date
MXPA04012970A true MXPA04012970A (es) 2005-08-18

Family

ID=30000613

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04012970A MXPA04012970A (es) 2002-06-20 2003-06-20 Preparacion farmaceutica y metodo de tratamiento de malignidad humana con carencia de arginina.

Country Status (12)

Country Link
US (4) US7951366B2 (https=)
EP (1) EP1517699B1 (https=)
JP (2) JP5307042B2 (https=)
CN (2) CN1918298B (https=)
AT (2) ATE385807T1 (https=)
AU (1) AU2002325782A1 (https=)
DE (2) DE60331871D1 (https=)
HK (1) HK1053577A2 (https=)
IL (1) IL165858A (https=)
MX (1) MXPA04012970A (https=)
NZ (1) NZ537774A (https=)
WO (1) WO2004001048A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745847A (zh) * 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20090068166A1 (en) * 2006-03-17 2009-03-12 Ning Man Cheng Method and composition for protection against radiation
US20080138858A1 (en) * 2006-12-12 2008-06-12 Bio-Cancer Treatment International Ltd. Expression System for Recombinant Human Arginase I
US8815232B2 (en) * 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
CA2742497C (en) * 2008-10-31 2024-01-23 George Georgiou Compositions of engineered human arginases and methods for treating cancer
AU2010242422B2 (en) * 2009-03-26 2014-12-04 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
CN103184208B (zh) 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
JP2016117702A (ja) * 2014-12-22 2016-06-30 武輝 山田 ガン細胞の死滅法
CN105062941B (zh) * 2015-08-25 2019-03-05 江南大学 一种利用重组枯草芽孢杆菌全细胞转化生产l-鸟氨酸的方法
US20180271960A1 (en) * 2015-09-21 2018-09-27 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
CN120661640A (zh) 2017-12-05 2025-09-19 伊梅尔迪卡制药公司 用于治疗精氨酸酶1缺乏症的方法和组合物
AU2019275733B2 (en) * 2018-05-31 2025-07-31 The Chinese University Of Hong Kong Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
KR20220082813A (ko) 2019-08-30 2022-06-17 아이글레아 바이오테라퓨틱스, 인크. 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용
US20210162028A1 (en) * 2019-12-02 2021-06-03 The Hong Kong Polytechnic University Methods for Inducing Intermittent Fasting and Modulating Autophagy
EP4169526A1 (en) * 2021-10-21 2023-04-26 Kyon Biotech AG Arginase based cancer therapy
CN115804845B (zh) * 2022-12-02 2025-09-30 华东理工大学 精氨酸剥夺在延缓衰老与联合化疗药物治疗肿瘤中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US5851985A (en) * 1996-08-16 1998-12-22 Tepic; Slobodan Treatment of tumors by arginine deprivation
AU5192498A (en) * 1996-12-03 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Tissue fibrosis inhibitor
WO1999043345A1 (en) 1998-02-26 1999-09-02 Eisai Co., Ltd. Amino acid degrading enzymes modulate cell death
US6413757B1 (en) * 2000-02-28 2002-07-02 Millennium Pharmaceuticals, Inc. 25312, a novel human agmatinase-like homolog
CN1324942A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶9和编码这种多肽的多核苷酸
CN1324945A (zh) * 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——精氨酸酶12和编码这种多肽的多核苷酸
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
DE10047204A1 (de) 2000-09-23 2002-04-25 Henkel Kgaa Topische Hautbehandlungsmittel mit Arginase
CN1345966A (zh) * 2000-09-26 2002-04-24 上海博德基因开发有限公司 一种新的多肽——人精氨酸酶35.42和编码这种多肽的多核苷酸
CN1345970A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——含精氨酸酶结构域的蛋白质9.35和编码这种多肽的多核苷酸
KR20040004449A (ko) 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
WO2003063780A2 (en) 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion

Also Published As

Publication number Publication date
HK1053577A2 (en) 2003-10-10
DE60331871D1 (de) 2010-05-06
IL165858A0 (en) 2006-01-15
ATE461707T1 (de) 2010-04-15
JP2010148509A (ja) 2010-07-08
US20080248018A1 (en) 2008-10-09
WO2004001048A1 (en) 2003-12-31
IL165858A (en) 2010-12-30
HK1071687A1 (en) 2005-07-29
EP1517699A1 (en) 2005-03-30
JP5307042B2 (ja) 2013-10-02
AU2002325782A1 (en) 2004-01-06
DE60319083D1 (de) 2008-03-27
US8679810B2 (en) 2014-03-25
US20080226617A1 (en) 2008-09-18
EP1517699B1 (en) 2008-02-13
US20050244398A1 (en) 2005-11-03
ATE385807T1 (de) 2008-03-15
CN1918298A (zh) 2007-02-21
CN101433714A (zh) 2009-05-20
NZ537774A (en) 2007-01-26
US7951366B2 (en) 2011-05-31
DE60319083T2 (de) 2009-02-05
HK1109876A1 (en) 2008-06-27
US20090123450A1 (en) 2009-05-14
CN1918298B (zh) 2011-06-29
JP2013172743A (ja) 2013-09-05

Similar Documents

Publication Publication Date Title
IL165858A0 (en) Pharmaceutical preparation and method for treatment of human malignancies with arginine deprivation
RU2006145899A (ru) Ферменты для фармацевтического применения
DE60115842D1 (de) Ventilanordnung
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
TW200503996A (en) Novel hydroxamates as therapeutic agents
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
AU2003225800A1 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
NZ623123A (en) A process for concentration of a polypeptide
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
MXPA05007822A (es) Terapia de combinacion para tratar trastornos de la deficiencia de proteinas.
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
HUP0301349A2 (hu) IL-11-tartalmú készítmények
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
ATE337712T1 (de) Zusammensetzung zur intestinalen verabreichung
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration

Legal Events

Date Code Title Description
FG Grant or registration